

**AWMSG ADVICE SUPERSEDED BY
NICE GUIDANCE (TA624)
NICE GUIDANCE ISSUED JANUARY 2020**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

**Final Appraisal Recommendation
Advice No: 1615 – June 2015**

**Peginterferon beta-1a (Plegridy[®]▼)
63 micrograms, 94 micrograms and 125 micrograms solution
for injection in pre-filled pen**

Submission by Biogen Idec Ltd

Recommendation of AWMSG

Peginterferon beta-1a (Plegridy[®]▼) is recommended as an option for use within NHS Wales in adult patients for the treatment of relapsing remitting multiple sclerosis.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2013), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Biogen Idec Ltd
Date of first issue	June 2015
Last reviewed	March 2019

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1615:
Peginterferon beta-1a (Plegridy[®]) 63 micrograms, 94 micrograms and 125 micrograms solution for injection in pre-filled pen. June 2015.

